Cargando…
Molecular subtyping of cancer and nomination of kinase candidates for inhibition with phosphoproteomics: Reanalysis of CPTAC ovarian cancer
BACKGROUND: Molecular subtyping of cancer aimed to predict patient overall survival (OS) and nominate drug targets for patient treatments is central to precision oncology. Owing to the rapid development of phosphoproteomics, we can now measure thousands of phosphoproteins in human cancer tissues. Ho...
Autores principales: | Tong, Mengsha, Yu, Chunyu, Zhan, Dongdong, Zhang, Ming, Zhen, Bei, Zhu, Weimin, Wang, Yi, Wu, Congying, He, Fuchu, Qin, Jun, Li, Tingting |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412074/ https://www.ncbi.nlm.nih.gov/pubmed/30594550 http://dx.doi.org/10.1016/j.ebiom.2018.12.039 |
Ejemplares similares
-
Phosphoproteomics Enables Molecular Subtyping and Nomination of Kinase Candidates for Individual Patients of Diffuse-Type Gastric Cancer
por: Tong, Mengsha, et al.
Publicado: (2019) -
Reproducibility
of Differential Proteomic Technologies
in CPTAC Fractionated Xenografts
por: Tabb, David L., et al.
Publicado: (2015) -
QC Metrics from CPTAC Raw LC-MS/MS Data Interpreted
through Multivariate Statistics
por: Wang, Xia, et al.
Publicado: (2014) -
Right data for right patient—a precisionFDA NCI–CPTAC Multi-omics Mislabeling Challenge
por: Boja, Emily, et al.
Publicado: (2018) -
Proteomic and Phosphoproteomic Reprogramming in Epithelial Ovarian Cancer Metastasis
por: Frederick, Mallory I., et al.
Publicado: (2023)